Herbert Skip Virgin
2021
In 2021, Herbert Skip Virgin earned a total compensation of $6.4M as Executive Vice President, Research and Chief Scientific Officer at Vir Biotechnology, a 480% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $368,939 |
|---|---|
| Option Awards | $3,278,340 |
| Salary | $655,621 |
| Stock Awards | $2,021,400 |
| Other | $95,600 |
| Total | $6,419,900 |
Virgin received $3.3M in option awards, accounting for 51% of the total pay in 2021.
Virgin also received $368.9K in non-equity incentive plan, $655.6K in salary, $2M in stock awards and $95.6K in other compensation.
Rankings
In 2021, Herbert Skip Virgin's compensation ranked 1,982nd out of 12,415 executives tracked by ExecPay. In other words, Virgin earned more than 84.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,982 out of 12,415 | 84th |
Division Manufacturing | 752 out of 5,505 | 86th |
Major group Chemicals And Allied Products | 291 out of 2,375 | 88th |
Industry group Drugs | 250 out of 2,096 | 88th |
Industry Biological Products, Except Diagnostic Substances | 78 out of 449 | 83rd |
Source: SEC filing on April 7, 2022.
Virgin's colleagues
We found four more compensation records of executives who worked with Herbert Skip Virgin at Vir Biotechnology in 2021.